Agomab Therapeutics shares tumble in Nasdaq debut as valuation hits 716 million dollars
The Belgian biotech firm saw its shares fall 8 percent during its Nasdaq debut on Friday. The company raised 200 million dollars to fund clinical development.
Insights:
Agomab Therapeutics completed its initial public offering in the United States 
US today, February 6, 2026, raising $200 million and debuting on the Nasdaq. The company, which has operations involving Belgium 
BE, achieved a market valuation of $716.4 million upon its entry into the public markets. Despite the successful capital raise, the company's shares experienced a decline of approximately 8% during their market debut.
US today, February 6, 2026, raising $200 million and debuting on the Nasdaq. The company, which has operations involving Belgium BE, achieved a market valuation of $716.4 million upon its entry into the public markets. Despite the successful capital raise, the company's shares experienced a decline of approximately 8% during their market debut.The completion of this IPO is a critical milestone that establishes the company's immediate capital position and market valuation. The listing took place during a period of heightened market volatility characterized by a broader sell-off in software and data-services stocks within the United States US. This downward pressure has made investors, including major market participants such as Blackstone Inc. , increasingly selective about new offerings.
US. This downward pressure has made investors, including major market participants such as Blackstone Inc. , increasingly selective about new offerings.
